- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Genetic resources.
Displaying page 1 of 1.
EudraCT Number: 2004-001719-77 | Sponsor Protocol Number: R115777-AML-301 | Start Date*: 2004-10-22 |
Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development | ||
Full Title: A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older. | ||
Medical condition: Treatment of Acute Myeloid Leukemia (AML) | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) SE (Completed) DK (Completed) IE (Completed) DE (Completed) ES (Completed) SK (Completed) IT (Completed) GB (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000756-17 | Sponsor Protocol Number: S61145 | Start Date*: 2018-05-30 | |||||||||||
Sponsor Name:KU Leuven | |||||||||||||
Full Title: Impact of Tight blood Glucose Control within normal fasting ranges with insulin titration prescribed by the Leuven algorithm in adult critically ill patients | |||||||||||||
Medical condition: Hyperglycemia in critically ill patients (stress hyperglycemia) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003884-71 | Sponsor Protocol Number: LPS13649 | Start Date*: 2015-02-05 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed) DK (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004277-27 | Sponsor Protocol Number: MT-1621-102 | Start Date*: 2019-07-16 |
Sponsor Name:Modis Therapeutics, Inc. | ||
Full Title: A Phase 2 open-label study of continuation treatment with combination pyrimidine nucleos(t)ides in patients with thymidine kinase 2 deficiency (TK2) | ||
Medical condition: Thymidine kinase 2 deficiency | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000918-37 | Sponsor Protocol Number: TRC112121 | Start Date*: 2014-06-20 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||||||||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high... | ||||||||||||||||||
Medical condition: Thrombocytopenic patients with myelodysplastic syndromes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) SE (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) GR (Prematurely Ended) IE (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) ES (Prematurely Ended) HU (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001842-34 | Sponsor Protocol Number: DOXIL-MMY-3001 | Start Date*: 2004-11-29 |
Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development | ||
Full Title: A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | ||
Medical condition: Recurred or relapsed multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) GB (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002851-27 | Sponsor Protocol Number: C16-40 | Start Date*: 2018-10-08 | ||||||||||||||||
Sponsor Name:INSERM | ||||||||||||||||||
Full Title: MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS - A phase III study | ||||||||||||||||||
Medical condition: Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001015-32 | Sponsor Protocol Number: AGO-OVAR17 | Start Date*: 2011-11-15 | |||||||||||
Sponsor Name:AGO Research GmbH | |||||||||||||
Full Title: A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian,... | |||||||||||||
Medical condition: Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIB - IV (all grades and all histological types) epithelial ovarian cancer, fallopian tube carcinoma or primary per... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) FI (Completed) NO (Completed) DK (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001663-24 | Sponsor Protocol Number: INSIGHT012 | Start Date*: 2021-09-20 | |||||||||||
Sponsor Name:Office of Sponsored Projects,University of Minnesota | |||||||||||||
Full Title: An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Out... | |||||||||||||
Medical condition: We are investigating Coronavirus disease 2019 (COVID-19) which is predominantly a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000801-39 | Sponsor Protocol Number: PsAer-IgY | Start Date*: 2011-08-31 | |||||||||||
Sponsor Name:Mukoviszidose Institute gGmbH | |||||||||||||
Full Title: Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention ... | |||||||||||||
Medical condition: Cystic fibrosis (CF) is a chronic and progressive genetic disease of the body's exocrine glands. CF especially affects the respiratory system. A common effect leads to massive production of abnorma... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) BE (Completed) IT (Completed) IE (Completed) HU (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
